Stock DNA
Pharmaceuticals & Biotechnology
CNY 10,651 Million (Mid Cap)
14.00
NA
2.13%
-0.19
14.58%
2.04
Revenue and Profits:
Net Sales:
1,723 Million
(Quarterly Results - Jun 2025)
Net Profit:
136 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.28%
0%
-24.28%
6 Months
-14.32%
0%
-14.32%
1 Year
-35.55%
0%
-35.55%
2 Years
-42.76%
0%
-42.76%
3 Years
5.87%
0%
5.87%
4 Years
40.9%
0%
40.9%
5 Years
36.09%
0%
36.09%
KPC Pharmaceuticals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.01%
EBIT Growth (5y)
15.09%
EBIT to Interest (avg)
15.66
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
1.18
Tax Ratio
20.51%
Dividend Payout Ratio
35.05%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.74%
ROE (avg)
10.11%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.04
EV to EBIT
11.37
EV to EBITDA
9.15
EV to Capital Employed
2.28
EV to Sales
1.19
PEG Ratio
0.21
Dividend Yield
2.13%
ROCE (Latest)
20.08%
ROE (Latest)
14.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,722.80
1,594.30
8.06%
Operating Profit (PBDIT) excl Other Income
176.40
185.40
-4.85%
Interest
13.70
13.70
Exceptional Items
1.30
0.20
550.00%
Consolidate Net Profit
136.40
113.60
20.07%
Operating Profit Margin (Excl OI)
73.50%
85.00%
-1.15%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 8.06% vs -45.31% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 20.07% vs -68.51% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8,319.50
8,346.00
-0.32%
Operating Profit (PBDIT) excl Other Income
1,008.80
900.40
12.04%
Interest
28.80
24.40
18.03%
Exceptional Items
4.90
-28.20
117.38%
Consolidate Net Profit
751.20
642.70
16.88%
Operating Profit Margin (Excl OI)
96.10%
81.40%
1.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -0.32% vs 1.66% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 16.88% vs 66.72% in Dec 2023
About KPC Pharmaceuticals, Inc. 
KPC Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






